$966M Talc Verdict Rocks J&J as Zantac, NEC, and Depo See Major Shifts
Автор: Jon and Marc
Загружено: 2025-10-16
Просмотров: 58
This week’s Tort Talks covers the major rulings and developments shaping the mass tort landscape one week before MTMP:
Talcum Powder: A $966 million verdict against J&J in a California mesothelioma trial raises pressure ahead of the first ovarian cancer bellwether set to begin November 3.
Zantac: Oral arguments at the Second Circuit challenge the MDL’s expert exclusion, a decision that could revive tens of thousands of claims and signal what’s ahead for Tylenol.
NEC: A new case management conference is expected to reset the bellwether schedule after earlier dismissals, with a push for backup cases to maintain trial momentum.
Depo-Provera: Case filings have doubled in just three months as a favorable ruling lets plaintiffs keep claims alive while awaiting the key preemption decision due before Thanksgiving.
👉 Your complete mass tort briefing for the week — in less than 10 minutes.
————————— Contents of this video —————————
00:00 – Intro: Tort Talks with Joe Fantini
00:25 – Talcum Powder: $966M Verdict and Ovarian Cancer Trial Preview
01:39 – Zantac: Second Circuit Oral Arguments and Tylenol Parallel
03:54 – NEC: Case Management Conference and Bellwether Framework
05:33 – Depo-Provera: Doubling Filings and Positive Rulings for Plaintiffs
07:14 – Closing: MTMP Preview and Next Week’s Updates
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
